Therapeutic Workshop
Novel Cancer MOA: "New Cancer-Killing Mechanisms"
Wednesday, February 13, 2008
9:30 AM
Jade Room
MEK, MET, BCL, HSV, ROS ? having trouble keeping track of all of the acronyms in today?s emerging cancer therapeutic pipeline vocabulary? Attend this panel to learn about the biological target, new drug profiles, cell cycle point of intervention and specificity and emerging use of biomarkers to create development continuity from non-clinical to clinical science and clinical progress behind these acronyms? promising cancer-killing methods-of-action.
Moderators
- Reni Benjamin; Analyst, Rodman and Renshaw
Panelists
- Dr. John Yates, MB, ChB, MD; CMO, Array BioPharma
- Dr. Daniel C. Adelman; Sr. Vice President and CMO, Sunesis Pharmaceuticals, Inc.
- Jim Barsoum; Synta Pharmaceuticals Corp., Sr. Vice President, Research
- Joseph Bolen; CSO, Millennium Pharmaceuticals, Inc.
- Kenneth Carter; President and CEO, Avalon Pharmaceuticals
- Neal Rosen, M.D., Ph.D.; Enid A. Haupt Chair in Medical Oncology, Memorial Sloan Kettering Cancer Center
Who's Who
Expert: Dr. Rosen is a Member in the Department of Medicine and in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School. His major interests are the identification and study of key molecular events and growth signaling pathways responsible for the development of human cancer and the use of this information for developing mechanism-based therapeutic strategies. He has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and has pioneered the concept that cancer cells are dependent on cellular machinery for protein folding. In the course of this work his laboratory has developed inhibitors of the Hsp90 protein chaperone and validated their anticancer activity in animal models and clinical trials. These inhibitors have now shown significant activity in patients with breast cancer, myelogenous leukemia and multiple myeloma. Currently his laboratory work focuses on using pharmacologic and genetic approaches to develop a detailed understanding of feedback and cross-talk among oncogene-activated pathways in order to develop rational combination therapy for refractory breast and lung cancer, melanoma and other tumors. Multiple novel clinical trials based on the work of the Rosen laboratory are being tested at Memorial Sloan-Kettering and other cancer centers in the United States and internationally. Dr. Rosen received his undergraduate degree in Chemistry from Columbia College and an MD, PhD in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women's Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer Institute. He was on the senior staff of the Medicine Branch at the NCI prior to joining the faculty